NFKB1 and rheumatoid arthritis: The goal of currently approved therapies in the treatment of RA is the use of biological disease-modifying antirheumatic drugs (bDMARDs), represent a breakthrough in RA treatment, and targeted synthetic DMARDs—based on JAKs/MAPKs/NF-κB/SYK-BTK signaling inhibitors [78].